AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29417902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (5 × 10^7 haMSCs)
Number of subjects: 18
Study 29417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose group (2 × 10^7 haMSCs)
Number of subjects: 18
Study 29417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (1 × 10^7 haMSCs)
Number of subjects: 18
Study 27335279 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy (TT) with 48°C water for 90 min
Number of subjects: 16
Study 27335279 — intervention group
Group type: COMPARATOR
Intervention: Control intervention with 33°C water
Number of subjects: 16
Study 25354998 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (hMSC)
Number of subjects: 36
Study 25354998 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic mesenchymal stem cells (allo-hMSCs)
Number of subjects: 36
Study 22461463 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volume-load (strength-power) training
Number of subjects: 18
Study 22461463 — intervention group
Group type: COMPARATOR
Intervention: Lower volume-load (speed-power) training
Number of subjects: 18
Study 19625388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 52
Study 19625388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18625864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the GPi
Number of subjects: 3
Study 18625864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation of the CM‐Pf
Number of subjects: 3
Study 18625864 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous thalamic and pallidal stimulation
Number of subjects: 3
Study 18625864 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot antipsychotic drugs (DA)
Number of subjects: 505
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: History of suicide
Number of subjects: 505
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine use
Number of subjects: 505
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP)
Number of subjects: 505
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: Admissions
Number of subjects: 505
Study 18538110 — intervention group
Group type: EXPERIMENTAL
Intervention: Study site (HK vs. BJ)
Number of subjects: 505
Study 15182776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1000
Study 15182776 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1000
Study 11252212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=49) received meal plans, recipes, and nutritional information during monthly group office sessions
Number of subjects: 97
Study 11252212 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=48) followed the National Cholesterol Education Program's Step II‐III diet plan
Number of subjects: 97
Study 11252212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=49)
Number of subjects: 97
Study 11252212 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 97
Study 9416938 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 16
Study 9416938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg 2 times daily)
Number of subjects: 16
Study 9416938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg 2 times daily) + Aspirin (325 mg/day)
Number of subjects: 16
Study 9416938 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) + Aspirin (325 mg/day)
Number of subjects: 16
Study 9416938 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 8295813 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 7.5 mg/kg twice daily, maximum 500 mg twice daily (n = 161)
Number of subjects: 338
Study 8295813 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 13.3 mg/kg three times daily, maximum 500 mg three times daily (n = 177)
Number of subjects: 338
Study 8295813 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 338
Study 8295813 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 338
Study 3091459 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin)
Number of subjects: 10000
Study 3091459 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 10000
Study 3091459 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of Fragmin (anti-FXa: 0.2-0.3 U/ml)
Number of subjects: 10000
Study 3091459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal application of Fragmin
Number of subjects: 10000
Study 11443185 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg as iv bolus at 2000 h, followed by 200 mg infused in 500 mL saline over 4 h up to 2400 h)
Number of subjects: 7
Study 11443185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 1.0 mL as iv bolus at 2000 h, followed by 500 mL over 4 h up to 2400 h)
Number of subjects: 7
Study 31796695 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish modified Story Memory Technique (mSMT), 10-session intervention
Number of subjects: 20
Study 31796695 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study 30346495 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder and Standard Information Booklet
Number of subjects: 1218
Study 30346495 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder and Theory‐Based Leaflet
Number of subjects: 1218
Study 30346495 — intervention group
Group type: COMPARATOR
Intervention: Control (no reminder)
Number of subjects: 1218
Study 26147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Number of subjects: 40
Study 26147635 — intervention group
Group type: COMPARATOR
Intervention: Topical pimecrolimus 1% cream
Number of subjects: 40
Study 26147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tacrolimus and pimecrolimus
Number of subjects: 40
Study 25258407 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 14 days
Number of subjects: 30
Study 22859389 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 75% 1RM, 2× volume (3 × 8, then 6 × 8 repetitions)
Number of subjects: 12
Study 22859389 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise at 75% 1RM, 1× volume (3 × 8, then 6 × 8 repetitions)
Number of subjects: 12
Study 22859389 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% 1RM, 2× volume (3 × 14, then 6 × 14 repetitions)
Number of subjects: 12
Study 22859389 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise at 40% 1RM, 1× volume (3 × 14, then 6 × 14 repetitions)
Number of subjects: 12
Study 20207689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Number of subjects: 7263
Study 20207689 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 7263
Study 18793544 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine (Crea)
Number of subjects: 105
Study 18793544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CyC)
Number of subjects: 105
Study 18793544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/Crea
Number of subjects: 105
Study 18793544 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsson formula
Number of subjects: 105
Study 18793544 — intervention group
Group type: COMPARATOR
Intervention: Cockroft and Gault (C&G)
Number of subjects: 105
Study 18793544 — intervention group
Group type: COMPARATOR
Intervention: MDRD
Number of subjects: 105
Study 16041739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrisin (three capsules/day)
Number of subjects: 65
Study 11812070 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve < 2.0 (n=109, 26%)
Number of subjects: 417
Study 11812070 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow velocity reserve >= 2.0
Number of subjects: 417
Study 10088846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (human)
Number of subjects: 47
Study 7585860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for induction and maintenance of anesthesia
Number of subjects: 1
Study 7585860 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/Isolurane
Number of subjects: 1
Study 2262649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide, 400 micrograms two times a day
Number of subjects: 36
Study 2262649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 443772 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 66
Study 443772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30706457 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream (TRE) every other night
Number of subjects: 61
Study 30706457 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day oral isotretinoin (ISO)
Number of subjects: 61
Study 30121097 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking with Teens about Traffic Safety Program (treatment group)
Number of subjects: 108
Study 30121097 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 108
Study 27018533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at increasing need-satisfying experiences
Number of subjects: 41
Study 27018533 — intervention group
Group type: COMPARATOR
Intervention: Neutral comparison
Number of subjects: 41
Study 25007421 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated violence reported by caregivers
Number of subjects: 72
Study 25007421 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver ratings of hostility expressed toward patients
Number of subjects: 72
Study 25007421 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver self-esteem and coping strategies
Number of subjects: 72
Study 25007421 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving situation
Number of subjects: 72
Study 25007421 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 72
Study 23427748 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 0
Study 23427748 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 20473056 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg intramuscular olanzapine
Number of subjects: 42
Study 20473056 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg orally disintegrating olanzapine tablets
Number of subjects: 42
Study 20473056 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mg oral risperidone solution
Number of subjects: 42
Study 20473056 — intervention group
Group type: COMPARATOR
Intervention: 7.5-mg intramuscular haloperidol
Number of subjects: 42
Study 17852863 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-generating solution
Number of subjects: 15
Study 17852863 — intervention group
Group type: COMPARATOR
Intervention: Control solution (hydrochloric acid pH 1.0)
Number of subjects: 15
Study 17852863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous acid solution
Number of subjects: 15
Study 16279576 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Monitoring Committees (DMCs) involvement in trials
Number of subjects: 45
Study 16279576 — intervention group
Group type: EXPERIMENTAL
Intervention: DMC policies from organizations
Number of subjects: 45
Study 12649048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 0
Study 12649048 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 0
Study 12649048 — intervention group
Group type: COMPARATOR
Intervention: Combination of dietary advice and exercise
Number of subjects: 0
Study 10805203 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-HFA 75 microg for 6 or 12 months
Number of subjects: 552
Study 10805203 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-HFA 225 microg for 6 or 12 months
Number of subjects: 552
Study 10805203 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-HFA 75 or 225 microg
Number of subjects: 552
Study 8980434 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 100
Study 8980434 — intervention group
Group type: COMPARATOR
Intervention: Control (no stripping)
Number of subjects: 100
Study 1479709 — intervention group
Group type: EXPERIMENTAL
Intervention: rEPO administered twice a week (group A)
Number of subjects: 42
Study 1479709 — intervention group
Group type: EXPERIMENTAL
Intervention: rEPO administered once a week (group B)
Number of subjects: 42
Study 1479709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 42
Study 6463067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 to 0.15 mg/kg) with suxamethonium (1 mg/kg)
Number of subjects: 37
Study 6463067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 to 0.15 mg/kg) with pancuronium (0.075 mg/kg)
Number of subjects: 37
Study 6463067 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium alone
Number of subjects: 37
Study 6463067 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium alone
Number of subjects: 37
Study 30383579 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 102
Study 30383579 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 102
Study 30513095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 16053
Study 30513095 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Number of subjects: 16053
Study 27068807 — intervention group
Group type: EXPERIMENTAL
Intervention: E-care 4 caregivers online intervention
Number of subjects: 84
Study 27068807 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 84
Study 25133471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.03 mg/kg per day or 0.06 mg/kg per day)
Number of subjects: 65
Study 25133471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25133471 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete monosomy Xp
Number of subjects: 65
Study 22995087 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 6789
Study 22995087 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 6789
Study 22995087 — intervention group
Group type: EXPERIMENTAL
Intervention: EES
Number of subjects: 6789
Study 22995087 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 6789
Study 20153142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent subjects (CD)
Number of subjects: 19
Study 20153142 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-using controls
Number of subjects: 19
Study 18373019 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (10000 lux)
Number of subjects: 24
Study 15716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 115
Study 15716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 115
Study 11834851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% with wet-wrap dressings
Number of subjects: 20
Study 11834851 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (steroid-free) with wet-wrap dressings
Number of subjects: 20
Study 9881313 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-hour training session in formulating questions and searching databases
Number of subjects: 108
Study 9881313 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 108
Study 8037876 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation for 3 months
Number of subjects: 0
Study 8037876 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2525897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 27
Study 2525897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol
Number of subjects: 27
Study 2525897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2525897 — intervention group
Group type: COMPARATOR
Intervention: Transdermal clonidine and Placebo
Number of subjects: 27
Study 30677506 — intervention group
Group type: EXPERIMENTAL
Intervention: roniciclib plus chemotherapy
Number of subjects: 140
Study 30677506 — intervention group
Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 140
Study 29136094 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (nutritional and exercise counselling and cognitive training)
Number of subjects: 1680
Study 29136094 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 supplementation (800 mg docosahexanoic acid and up to 225 mg eicosapentanoic acid)
Number of subjects: 1680
Study 29136094 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega-3 supplementation
Number of subjects: 1680
Study 29136094 — intervention group
Group type: COMPARATOR
Intervention: Placebo with usual care
Number of subjects: 1680
Study 29136094 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 plus usual care
Number of subjects: 1680
Study 26508094 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (40 mg BID ABT‐888 with 75 mg/m² TMZ for 21 days)
Number of subjects: 225
Study 26508094 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (40 mg BID ABT‐888 with 150-200 mg/m² TMZ for 5 days)
Number of subjects: 225
Study 26508094 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ/ABT‐888 (both arms)
Number of subjects: 225
Study 26508094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 225
Study 24821941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine±perindopril
Number of subjects: 2069
Study 24821941 — intervention group
Group type: COMPARATOR
Intervention: Atenolol±bendroflumethiazide
Number of subjects: 2069
Study 24821941 — intervention group
Group type: EXPERIMENTAL
Intervention: XSPI
Number of subjects: 2069
Study 24821941 — intervention group
Group type: EXPERIMENTAL
Intervention: XSPI, central systolic blood pressure, central augmentation pressure, central pulse pressure, integral of reservoir pressure
Number of subjects: 2069
Study 24821941 — intervention group
Group type: EXPERIMENTAL
Intervention: XSPI, augmentation pressure, central pulse pressure
Number of subjects: 2069
Study 24821941 — intervention group
Group type: EXPERIMENTAL
Intervention: XSPI, integral of reservoir pressure
Number of subjects: 2069
Study 22836034 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 22
Study 22836034 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight control subjects
Number of subjects: 22
Study 20601383 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention programme (video and discussion groups)
Number of subjects: 1071
Study 20601383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1071
Study 20601383 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention programme
Number of subjects: 1071
Study 17427602 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational Family Interventions (PFI)
Number of subjects: 0
Study 17427602 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 17427602 — intervention group
Group type: COMPARATOR
Intervention: Individual integrated interventions
Number of subjects: 0
Study 17427602 — intervention group
Group type: COMPARATOR
Intervention: Different PFI strategies
Number of subjects: 0
Study 17427602 — intervention group
Group type: COMPARATOR
Intervention: Implementation studies
Number of subjects: 0
Study 16287051 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy and routine care
Number of subjects: 64
Study 16287051 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 64
Study 12058514 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy training
Number of subjects: 895
Study 12058514 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 895
Study 9865017 — intervention group
Group type: EXPERIMENTAL
Intervention: Metopress-retard 100 mg taken at 8 a.m.
Number of subjects: 38
Study 9865017 — intervention group
Group type: EXPERIMENTAL
Intervention: Metopress-retard 100 mg taken at 8 p.m.
Number of subjects: 38
Study 7783666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (2.5 to 20 g in iso-osmolar solutions)
Number of subjects: 113
Study 7783666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g)
Number of subjects: 113
Study 7783666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (up to 10 g)
Number of subjects: 113
Study 7783666 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no specific intervention mentioned)
Number of subjects: 113
Study 2547300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fiber (PF) 15 g
Number of subjects: 0
Study 2547300 — intervention group
Group type: COMPARATOR
Intervention: Sugar beet fiber (BF)
Number of subjects: 0
Study 2547300 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 0
Study 2547300 — intervention group
Group type: COMPARATOR
Intervention: Control meal (150 g ground beef, 50 g glucose, 20 g lactulose)
Number of subjects: 0
Study 1264003 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 113
Study 1264003 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113
Study 7316247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 0
Study 7316247 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 0